Stock Analiz

Avalo Therapeutics, Inc. AVTX

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$7.76Market cap $449M
Open the interactive analysis →

Avalo Therapeutics, Inc. (AVTX) is a healthcare company listed in the US with a market value of about $449M. In the twelve months to September 30, 2026 it had revenue of $59000 and net income of -$89M, a net margin of -150259.3%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -61% a year, a 5-year average ROIC of -146%.

About Avalo Therapeutics

Avalo Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $1M in 2016 to $59000 in 2025, a decline of about 28.1% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 34094% over three years (dilution for shareholders). It spends 84888% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S7,605.0
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-14.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-86.6%
Revenue growth (5 yrs, per year)-61.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-28799.8%
ROIC (5-yr avg.)-146.1%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$59000$59000$441000$2M$18M$5M$7M$7M$7M$28M$1M
Net income-$89M-$78M-$35M-$32M-$42M-$84M-$64M-$16M-$40M$12M-$16M
Free cash flow-$63M—-$49M-$31M-$27M-$71M-$41M-$19M-$4M$13M-$15M
EPS (diluted)$-2.52$-5.84$-20.91$-113.58$-1063.00———$-288.00$100.80$-448.80
Net margin-150259.3%-132600.0%-7965.8%-1639.5%-230.8%-1563.1%-947.9%-238.1%-569.9%42.7%-1428.6%
ROIC—-69.0%-40.4%-234.7%-275.3%-111.1%-221.1%-57.3%-77.0%39.4%-496.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $34.80, 348% above the current price; targets range from $10.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-2.35 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Avalo Therapeutics pay a dividend?

Not currently.

Is Avalo Therapeutics a good stock to buy?

We do not give buy or sell advice. Avalo Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.